Assessing Multi-Modality Breast Cancer Screening Strategies for BRCA 1/2 Gene Mutation Carriers and Other High-Risk Populations

2018 ◽  
Author(s):  
aalar aalayan ◽  
Turgay Ayer ◽  
Donatus U. Ekwueme
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Breast Cancer Screening ◽  
Gene Mutation ◽  
Mutation Carriers ◽  
Screening Strategies ◽  
Brca 1 ◽  
High Risk Populations

Breast cancer screening in high risk populations

2012 ◽  
Vol 54 (6) ◽  
pp. 490-502
Author(s):  
S. Alonso Roca ◽  
S. Jiménez Arranz ◽  
A.B. Delgado Laguna ◽  
V. Quintana Checa ◽  
E. Grifol Clar
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Breast Cancer Screening ◽  
High Risk Populations

scholarly journals Breast Cancer Screening Trials: Endpoints and Overdiagnosis

2020 ◽  
Author(s):  
Ismail Jatoi ◽  
Paul F Pinsky
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
Breast Cancer Screening ◽  
Cancer Detection ◽  
Primary Endpoint ◽  
Tumor Detection ◽  
Breast Cancer Detection ◽  
Detection Rates ◽  
Screening Strategies ◽  
Screening Trials

Abstract Screening mammography was assessed in 9 randomized trials initiated between 1963 and 1990, with breast cancer-specific mortality as the primary endpoint. In contrast, breast cancer detection has been the primary endpoint in most screening trials initiated during the past decade. These trials have evaluated digital breast tomosynthesis, magnetic resonance imaging, and ultrasound, and novel screening strategies have been recommended solely on the basis of improvements in breast cancer detection rates. Yet, the assumption that increases in tumor detection produce reductions in cancer mortality has not been validated, and tumor-detection endpoints may exacerbate the problem of overdiagnosis. Indeed, the detection of greater numbers of early stage breast cancers in the absence of a subsequent decline in rates of metastatic cancers and cancer-related mortality is the hallmark of overdiagnosis. There is now evidence to suggest that both ductal carcinoma in situ and invasive cancers are overdiagnosed as a consequence of screening. For each patient who is overdiagnosed with breast cancer, the adverse consequences include unnecessary anxiety, financial hardships, and a small risk of morbidity and mortality from unnecessary treatments. Moreover, the overtreatment of breast cancer, as a consequence of overdiagnosis, is costly and contributes to waste in health-care spending. In this article, we argue that there is a need to establish better endpoints in breast cancer screening trials, including quality of life and composite endpoints. Tumor-detection endpoints should be abandoned, because they may lead to the implementation of screening strategies that increase the risk of overdiagnosis.

scholarly journals Breast cancer screening in high risk women

2008 ◽  
Vol 8 (Special Issue A) ◽  
pp. S6-S9 ◽  
Author(s):  
Fiona J. Gilbert
Keyword(s):  
Breast Cancer ◽  
Cancer Screening ◽  
High Risk ◽  
Breast Cancer Screening ◽  
High Risk Women

scholarly journals Cost-effectiveness of MRI compared to mammography for breast cancer screening in a high risk population

2009 ◽  
Vol 9 (1) ◽  
Author(s):  
Susan G Moore ◽  
Pareen J Shenoy ◽  
Laura Fanucchi ◽  
John W Tumeh ◽  
Christopher R Flowers
Keyword(s):  
Breast Cancer ◽  
Cost Effectiveness ◽  
Cancer Screening ◽  
High Risk ◽  
Breast Cancer Screening ◽  
High Risk Population ◽  
Risk Population
Sign in / Sign up

Export Citation Format

Share Document